EP0661970A1 - Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure - Google Patents

Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure

Info

Publication number
EP0661970A1
EP0661970A1 EP92925405A EP92925405A EP0661970A1 EP 0661970 A1 EP0661970 A1 EP 0661970A1 EP 92925405 A EP92925405 A EP 92925405A EP 92925405 A EP92925405 A EP 92925405A EP 0661970 A1 EP0661970 A1 EP 0661970A1
Authority
EP
European Patent Office
Prior art keywords
amlodipine
amount
composition according
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92925405A
Other languages
German (de)
English (en)
Other versions
EP0661970A4 (fr
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to EP02019389A priority Critical patent/EP1262182A3/fr
Priority to EP05107608A priority patent/EP1614420A3/fr
Priority to EP99123828A priority patent/EP1013275A3/fr
Publication of EP0661970A4 publication Critical patent/EP0661970A4/fr
Publication of EP0661970A1 publication Critical patent/EP0661970A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • compositions of matter containing optically pure (-) amlodipine possess potent activity in treating both systolic and diastolic hypertension while avoiding adverse effects including but not limited to edema of the extremities, headache and dizziness, which are associated with administration of the racemic mixture of amlodipine.
  • compositions of matter containing optically pure ⁇ -) amlodipine are useful in treating angina and such other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist including but not limited to cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure — while avoiding the adverse effects associated with administration of the racemic mixture of amlodipine.
  • Stereochemical purity is of importance in the field of pharmaceuticals, where 12 of the 20 most prescribed drugs exhibit chirality.
  • a case in point is provided by the L-form of the /S-adrenergic blocking agent, propranolol, which is known to be 100 times more potent than the D-enantiomer.
  • optical purity is important since certain isomers may actually be deleterious rather than simply inert.
  • D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, while the corresponding L-enantiomer has been thought to be a potent teratogen.
  • the active compound of this composition and method is an optical isomer of the compound amlodipine, which is described in Davison et al. , United States Patent No. 4,572,909. Chemically, this (-) isomer is 3-ethyl 5-methyl (-)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridine-dicarboxylate. This isomer will hereinafter be referred to as (-) amlodipine.
  • Amlodipine also includes the substantially optically pure (-) amlodipine isomer.
  • Amlodipine which is the subject of the present invention, is available commercially only as the 1:1 racemic mixture. That is, it is available only as the 1:1 mixture of optical isomers, called enantiomers.
  • the racemic mixture of amlodipine that is commercially available for administration is a besylate salt.
  • the pharmacologic class of calcium antagonists consists of chemically diverse compounds. Given the structural heterogeneity of the class it is likely that the pharmacological action involves more than one site or mechanism of action.
  • Amlodipine is one of a series of dihydropyridine calcium antagonists. However, amlodipine has a generally slower onset and longer duration of action than, for example, nifedipine. (Jensen, H. et al., J. Hum . Hypertens . , 4 (5) : 541-45, 1990) .
  • the racemic mixture of amlodipine produces peripheral vasodilation, resulting in decreases in both systolic and diastolic blood pressure when used as an antihypertensive agent.
  • This antihypertensive effect occurs in the relative absence of significant or sustained effects on cardiac rate.
  • hypertension appears to be the product of an inherited predisposition — coupled with dietary, emotional, and environmental factors, which results in a structural adaptation of the cardiac muscle and the large blood vessels. Most patients display heightened vascular and cardiac reactions to sympathetic nervous stimulation, but the precise relationship of sympathetic nervous stimulation to the etiology of the disease. Nevertheless, hypertension results in chronic readjustment of cardiovascular hemodynamics, alteration of blood vessel walls, cardiovascular resistance and regional transmural pressures.
  • Pharmacologic management of hypertension is generally directed to the normalization of altered hemodynamic parameters, and many drugs and drug classes, either as monotherapy or in combination treatment, can reduce and control elevated blood pressure.
  • treatment of hypertension does not always correspondingly benefit the morbidity and mortality of the condition, either because chronic hypertension has produced other significant and irreversible cardiovascular changes, or because present drugs have an adverse effect on some other risk factor for cardiovascular disease. Rather, current drug therapy simply provides sustained arterial pressure reduction.
  • racemic mixture of amlodipine is useful in treating other disorders such as angina pectoris.
  • Angina pectoris is a highly variable, rather poorly understood clinical syndrome reflecting a myocardial ischemia.
  • cardiac work or myocardial oxygen demand exceeds the ability of the coronary arterial vascular system to supply oxygen, the resulting ischemia stimulates the sensory nerves of the heart, producing the sensation of angina characterized by episodes of precordial pressure, discomfort, or a severe, intense crushing pain which may radiate to several sites including the left shoulder and left arm.
  • Physical activity or exertion characteristically initiates the condition, and rest or drug therapy relieves the condition.
  • the signs and symptoms of an episode persist for a few minutes, but can be induced or exaggerated by a meal or exposure to cold air.
  • Treatment is directed to the underlying disease, usually atherosclerosis, or to drugs which either reduce myocardial oxygen demand or improve oxygen supply.
  • Calcium antagonists such as amlodipine have been particularly useful in treating vasospastic angina, the angina of effort, and the unstable angina, due to the effect of the calcium channel antagonist on cardiac and vascular smooth muscle.
  • Amlodipine may be useful in the treatment of cerebral ischemia. Cerebral ischemia, often the result of atherosclerotic disease or hypertension, results from insufficient cerebral circulation. Under normal circumstances, an extensive collateral circulation ensures adequate blood flow. However, cerebral ischemia may result from either an intra- or extracranial interruption of arterial blood flow. If interruption is transient, the cerebral tissues recover, and neurologic symptoms disappear. If the ischemia lasts for a somewhat more extended period, infarction results and the resulting neurologic damage is permanent. In the case of extended ischemia resulting in infarction, treatment is directed to the underlying vascular disease, to blood platelet aggregation inhibitors, and anticoagulant therapy.
  • amlodipine may also be useful in treating cardiac arrhythmias.
  • Cardiac arrhythmias represent a broad, complex group of electrophysiologic disorders that affect the mechanical properties of the heart and vasculature, altering normal cardiac rhythm, function and output. Normal cardiac rhythm originates with the sinoatrial node, which possesses high intrinsic automaticity. Adequate automaticity and conduction lead to activation of atrial and ventricular fibers, producing in sequence the elements of normal functional heart beat.
  • Calcium antagonists may be of value in conditions where calcium-related changes in membrane potential and conduction alter normal rhythm.
  • Amlodipine may be useful to treat cardiac hypertrophy. Cardiac hypertrophy can result from excessive workload either due to an obstruction to outflow, termed systolic overload, or to excessive volumes presented to the heart in diastole, termed diastolic overload. Systolic overload results in concentric ventricular hypertrophy, in which there is an increased thickness in the walls of the heart not associated with increased volume. Diastolic overload causes dilation and hypertrophy with an increased blood volume.
  • Calcium channel antagonists effect workload and, as such, may be useful in treating cardiac hypertrophy due to the effect of the calcium antagonist on cardiac and vascular smooth muscle in reducing blood pressure.
  • amlodipine could be used to treat coronary arterial spasm.
  • Coronary arterial spasm can occur in the absence of significant coronary atherosclerosis and is thought to be an initiating event in variant angina and in myocardial infarction. Coronary spasm may occur without the patient feeling any significant discomfort.
  • diverse neural impulses to the heart may provoke coronary vascular spasm. This may result in enhanced myocardial ischemia and arrhythmia, which in turn may culminate in ventricular fibrillation and sudden cardiac death.
  • the calcium channel antagonists may be of particular usefulness due to their effect on cardiac and vascular smooth muscle.
  • amlodipine may be useful in the treatment of myocardial infarction, ischemic myocardial necrosis, and ischemia reperfusion injury.
  • Myocardial infarction or ischemic myocardial necrosis generally results from the abrupt reduction of coronary blood flow to a portion of the myocardium.
  • the condition likely originates from atherosclerosis of the coronary arteries. • Either coronary artery vasospasm or acute coronary thrombosis precipitates the condition, although the etiology is the subject of continuing research.
  • Myocardial infarction is predominantly a disease of the left ventricle. Precordial pain and left ventricular dysfunction characterize the disease.
  • the pain which can be severe aching or pressure, leads to apprehension.
  • Symptoms include left ventricular heart failure, pulmonary edema, shock or significant cardiac arrhythmia.
  • Calcium channel antagonists may find utility in the management of myocardial infarction patients due to their effects on coronary artery vasospasm, blood pressure or other effects on cardiac function or vascular smooth muscle.
  • Amlodipine may be used to treat congestive heart failure.
  • Congestive heart failure can be caused by hypertension, cardiomyopathy, coronary artery disease or valvular heart disease. Congestive failure results in poor cardiac output and elevated left- ventricular diastolic pressure, leading to dyspnea, fatigue, peripheral edema, and coughing.
  • the ability of some calcium antagonists to lower afterload by dilating peripheral arteries without having a significant inotropic effect may increase their use in treating congestive heart failure.
  • Amlodipine may be of use in treating migraine.
  • Classic migraine typically begins with visual auras followed by severe headaches, often accompanied by nausea and vomiting.
  • Common migraine has similar symptoms without the preceding visual aura.
  • the causes of migraine have been studied intensely, and are still a matter of debate. The most generally accepted cause is hypoxia due to reduced cerebral blood flow.
  • Calcium channel antagonists have been used for migraine prophylaxis since they can increase cerebral blood flow.
  • Amlodipine may also be useful for treating Raynaud's phenomenon, which is characterized by vascular spasm of the extremities. These vasospas s can be caused by cold or stress. A pallor or cyanosis is usually present due to severe constriction of the digital arteries. The phenomenon is often seen as a secondary disorder with arterial diseases or connective tissue diseases such as scleroderma, arthritis or lupus erythematosus. Calcium channel antagonists have been shown to be effective in treating Raynaud's phenomenon.
  • Amlodipine may be useful in the treatment of asthma and bronchospasm. Symptoms of asthma - coughing, wheezing, and dyspnea - are caused by constriction of tracheobronchial smooth muscle. Asthma attacks can be triggered by antigenic stimuli (pollen, dust) or non-antigenic stimuli (exercise, pollution, infection) .. The response to these stimuli lead to secretions of chemical mediators that cause smooth muscle contraction. Calcium channel antagonists can be used to control bronchoconstriction and relieve asthma attacks. In addition, the racemic mixture of amlodipine may be useful to treat renal impairment and acute renal failure.
  • Renal impairment and acute renal failure are clinical conditions of diverse etiology, which, are associated with an increasing azotemia or urea nitrogen in the blood, and often an oliguria or a diminished volume of urine in relation to fluid intake.
  • the pathophysiology may originate prerenallv. manifest as inadequate renal perfusion, due to extracellular fluid volume depletion or cardiac failure.
  • the most common cause of intrinsic renal failure is prolonged renal ischemia.
  • Postrenal azote ia may be associated with obstruction or renal glomerular and tubular dysfunction.
  • Laboratory findings disclose progressive azotemia, acidosis, hyperkalemia, and hyponatremia. Factors aggravating kidney impairment or failure must be specifically treated, including heart failure, obstruction and the like. Moderate or severe hypertension has a deleterious effect on renal function, and management of the hypertension with a variety of drugs including calcium channel antagonists may be useful therapy.
  • racemic mixture of amlodipine could be useful in the treatment of cognitive disorders.
  • Cognitive disorders include but are not limited to dementia and age-associated memory impairment.
  • Dementia can occur at any age. It is a structurally caused permanent or progressive decline in several dimensions of intellectual function that interferes substantially with individual normal social or economic activity.
  • Alzheimers-type dementia One particular type of dementia is Alzheimers-type dementia.
  • Alzheimers-type of dementia is thought to be due to a degenerative process, with a large loss of cells from the cerebral cortex and other brain areas. Acetylcholine-transmitting neurons and their target nerve cells are particularly affected.
  • the brain shows marked atrophy with wide sulci and dilated ventricles. Senile plaques and neurofibrillary tangles are present. Memory loss is the most prominent early symptom. Disturbances of arousal do not occur early in the course.
  • Alzheimer's presenile and senile onset dementias are similar in both clinical and pathologic features, with the former commonly beginning in the 5th and 6th decades and the latter in the 7th and 8th decades. The dementia usually progresses steadily, becoming well advanced in 2 to 3 years. Some cases of dementia occurring in the presenile period are hard to classify and are sometimes labelled idiopathic or simple presenile dementia.
  • AAMI age-associated memory impairment
  • optically pure (-) isomer of amlodipine is an effective antihypertensive agent for both systolic and diastolic hypertension, particularly in mild to moderate disease and angina, while avoiding adverse effects including but not limited to edema of the extremities, headache and dizziness, which are associated with the administration of the racemic mixture of amlodipine.
  • compositions of matter containing optically pure (-) amlodipine are useful in treating other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist, including but not limited to cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure while avoiding the above-described adverse effects associated with the administration of the racemic mixture of amlodipine.
  • the present invention also includes methods for treating the above-described conditions in a human while avoiding the adverse effects that are associated with the racemic mixture of amlodipine by administering the (-) isomer of amlodipine to said human.
  • the present invention encompasses a method of eliciting an antihypertensive effect in a human, while avoiding the concomitant liability of adverse effects, which comprises administering to said human in need of such antihypertensive therapy, an amount of (-) amlodipine or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate hypertension, but insufficient to cause said adverse effects associated with administration of racemic amlodipine.
  • the present invention also encompasses an antihypertensive composition for the treatment of a human in need of antihypertensive therapy, which comprises an amount of (-) amlodipine or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate said hypertension but insufficient to cause adverse effects of racemic amlodipine.
  • the present invention further encompasses a method of treating angina in a human, while avoiding the concomitant liability of adverse effects, which comprises administering to said human in need of such anti-angina therapy, an amount of (-) amlodipine, or a pharmaceutically acceptable salt thereof.
  • the present invention encompasses an antianginal composition for the treatment of a human having angina, which comprises an amount of (-) amlodipine or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate said angina but insufficient to cause adverse effects of racemic amlodipine.
  • a further aspect of the present invention includes a method of treating a condition caused by excessive calcium influx in cells in a human, while avoiding the concomitant liability of adverse effects, which comprises administering to said human in need of a reduction in excessive calcium influx an amount of (-) amlodipine, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, sufficient to alleviate said condition but insufficient to cause said adverse effects of racemic amlodipine.
  • Conditions caused by excessive calcium influx in cells in a human include but are not limited to cerebral ischemia, cerebral disorders such as cognitive disorders including but not limited to Alzheimer's dementia and memory impairment, arrhythmias, cardiac hypertrophy, congestive heart failure, coronary vasospasm, migraine, bronchospasm and asthma, Raynaud's phenomenon, myocardial infarction, renal impairment and acute renal failure.
  • the present invention includes a composition for treating a condition caused by excessive calcium influx in cells in a human, which comprises an amount of (-) amlodipine, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer, said amount being sufficient to alleviate said condition but insufficient to cause adverse effects of racemic amlodipine.
  • the commercially available racemic mixture of amlodipine e.g.. a 1:1 racemic mixture of the two enantiomers
  • Utilizing the (-) isomer of amlodipine results in clearer dose-related definitions of efficacy, surprisingly diminished adverse effects, and accordingly, an improved therapeutic index. It is, therefore, more desirable to use the (-) isomer of amlodipine.
  • cardiovascular effects including tachycardia and diminished contractility of the heart
  • edema of the extremities headache, dizziness, flushing, fatigue, vertigo, and muscle cramps.
  • the term "substantially free of its (+) stereoisomer” as used herein means that the composition contains a greater proportion or percentage of the (-) isomer of amlodipine in relation to the (+) isomer of amlodipine, said percentage being based on the total amount of amlodipine.
  • the term "substantially free of its (+) stereoisomer” means that the composition contains at least 90% by weight of (-) amlodipine, and 10% by weight or less of (+) amlodipine.
  • the term "substantially free of the (+) stereoisomer” means that the composition contains at least 99% by weight (-) amlodipine, and 1% or less of (+) amlodipine.
  • the term "substantially free of its (+) stereoisomer” as used herein means that the composition contains 100% by weight of (-) amlodipine.
  • the terms “substantially optically pure (-) isomer of amlodipine” and “optically pure (-) isomer of amlodipine are also encompassed by the above-described meanings.
  • eliciting an antihypertensive effect means providing a normalization to otherwise elevated systolic and/or diastolic blood pressure, and by so doing providing relief from any possible symptoms or other hemodynamic effects caused by the elevated pressure.
  • a method of treating angina means relief from the symptoms of myocardial ischemia, which include, but are not limited to, episodes of precordial pressure, discomfort, or a severe intense, crushing pain which may radiate, and which may be accompanied by changes in respiration, pulse rate, and blood pressure.
  • a condition caused by excessive calcium influx in cells in a human includes but is not limited to conditions involving calcium influx in human cell that may be present in smooth muscle, cardiac, and other tissues including lung and brain. These conditions include, but are not limited to, cerebral ischemia, cerebral disorders such as cognitive disorders including Alzheimer's dementia and memory impairment, arrhythmias, cardiac hypertrophy, congestive heart failure, coronary vasospasm, migraine, bronchospasm and asthma, Raynaud's phenomenon, myocardial infarction, renal impairment and acute renal failure.
  • the symptoms associated with these disorders include, but are not limited to, the symptoms of precordial discomfort or pain, headache, fatigue, decreased exercise tolerance, syncope, shortness of breath, nausea, lightheadedness, edema, pulmonary congestion, arrhythmia or palpitation, azotemia, and/or oliguria.
  • the chemical synthesis of the racemic mixture of amlodipine can be performed by the method described in Arrowsmith, J.E. et al., J. Med. Chem. , 29: 1696-1702 (1986) .
  • the racemic acid 1 is converted to its cinchonidine salts in methanol solution. Upon dilution with water and standing at room temperature, a crystalline precipitate is formed which can be subsequently recrystallized to constant rotation to give the diastereomerically pure cinchonidine salt 2. Further, the mother liquids from the original crystallization can be reduced in volume and stirred at room temperature, e.g. overnight, to afford a fine precipitate which can also be recrystallized to give the diastereomerically pure cinchonidine salt 2. The cinchonidine salt 2 is partitioned between ethyl acetate and dilute hydrochloric acid to liberate the (+) acid 3.
  • the acid 3 is then esterified using carbonyldimidazole (CDI) in near-quantitative yield by forming an imidazolide and decomposing the imidazolide with ethanolic sodium ethoxide to give 4.
  • CDI carbonyldimidazole
  • the azido group in 4 can then be cleanly reduced to amino by catalytic hydrogenation, giving (-) amlodipine, which is most conveniently isolated as the salt of an acid, e.g. as the maleate 5.
  • the magnitude of a prophylactic or therapeutic dose of (-) amlodipine in the acute or chronic management of disease will vary with the severity of the condition to be treated and the route of administration.
  • the dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual patient.
  • the total daily dose ranges, for the conditions described herein is from about 0.01 mg. to about 100.0 mg.
  • a daily dose range should be between about 0.5 mg to about 20.0 mg. while most preferably, a daily dose range should be between about 0.5 mg to about 10 mg.
  • the therapy should be initiated at a lower dose, perhaps about 0.025 mg to about 2.5 mg and increased up to about 20 mg or higher depending on the patient's global response. It is further recommended that children and patients over 65 years, and those with impaired renal or hepatic function, initially receive low doses, and that they be titrated based on global response and blood level. It may be necessary to use dosages outside these ranges in some cases.
  • an amount sufficient to alleviate hypertension but insufficient to cause said adverse effects is angina; and “an amount sufficient to alleviate said condition but insufficient to cause said adverse effects” wherein said condition includes but is not limited to cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure are encompassed by the above described dosage amounts and dose frequency schedule.
  • Any suitable route of administration may be employed for providing the patient with an effective dosage of (-) amlodipine.
  • oral, rectal, parenteral, transdermal, subcutaneous, intramuscular, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like.
  • compositions of the present invention comprise (-) amlodipine as active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic acids and organic acids. Since the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • Such acids include acetic, benzene-sulfonic (besylate) , benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like.
  • Particularly preferred are besylate, hydrobromic, hydrochloric, phosphoric and sulfuric acids. (See Campbell, S.F. et al., US 4,806,557.)
  • compositions include compositions suitable for oral, rectal and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated.
  • the most preferred route of the present invention is the oral route.
  • the compositions may be conveniently presented in unit dosage form, and prepared by any of the methods well known in the art of pharmacy.
  • a suitable dosage range for use is from about 0.01 mg. to about 100.0 mg. total daily dose, given as a once daily administration in the morning or in divided doses if required.
  • a dose range of between about 0.5 mg to about 20.0 mg is given as a once daily administration or in divided doses if required, and most preferably a dose range of from between about 0.5 mg to about 10.0 mg is given as a once daily administration or in divided doses if required.
  • Patients may be upward titrated from below to within this dose range to a satisfactory control of symptoms or blood pressure as appropriate.
  • (-) amlodipine can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of the preparation desired for administration, e.g., oral or parenteral (including intravenous injections or infusions) .
  • parenteral including intravenous injections or infusions
  • any of the usual pharmaceutical media may be employed.
  • Usual pharmaceutical media include, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as for example, suspensions, solutions, and elixirs) ; aerosols; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like, in the case of oral solid preparations (such as for example, powders, capsules, and tablets) with the oral solid preparations being preferred over the oral liquid preparations.
  • oral liquid preparations such as for example, suspensions, solutions, and elixirs
  • aerosols or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like
  • oral solid preparations such as for example, powders, capsules, and tablets
  • the most preferred oral solid preparation is tablets.
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
  • the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S.Patent Nos. : 3,845,770; 3,916,899; 3,536,809;
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosols sprays, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous.liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or molding, optionally, with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, and/or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • each tablet contains from about 0.01 mg to about 50 mg of the active ingredient, and each cachet or capsule contains from about 0.5 mg to about 50 mg of the active ingredient, (-) amlodipine.
  • the tablet, cachet or capsule contains either one of three dosages, 0.5 mg, 2.5 mg and 5.0 mg (as scored tablets, the preferable dose form) of the active ingredient.
  • the relative potency of optically pure (-) amlodipine and racemic amlodipine as calcium channel antagonists and negative inotropic agents are determined by a pharmacological study. Evaluation of these compounds and others in in vitro test systems provide results, from which the vascular selectivity of a particular compound can be assessed.
  • Calcium channel antagonist activity of the compounds as a function of their molar concentration can be evaluated by measuring their inhibition of the calcium-induced contraction of strips of rat aorta immersed in a bath of Krebs-Henseleit buffer containing 45mM K + and no Ca 2+ . In the presence of various concentrations of the antagonists, inhibition would occur in the contraction of this isolated tissue preparation in response to the addition of calcium chloride.
  • Antagonists may be compared by examining the molar concentration of compounds inhibiting the calcium-induced contraction by 50%.
  • negative inotropic activity may be comparably assessed using isolated heart preparations of adult rats.
  • the tissues are prepared and perfused in vitro with Krebs- Henseleit buffer solution, with the activity of the calcium channel antagonists evaluated as a function of their concentration.
  • the compounds are tested for their ability to alter cardiac contraction. Relative potency is calculated from the IC ⁇ values of the compounds, i.e. , the concentration required to depress contraction by 25%.
  • the hearts are removed and perfused with Krebs-Henseleit solution at constant pressure (60 cm water) by means of retrograde cannulation of the aorta in a Langendorff apparatus.
  • the Krebs-Henseleit solution consisting 0 of 118.0 mM NaCl, 4.7 mM KC1, 5.5 mM CaCl 2 , 1.2 mM
  • MgS0 4 25.0 mM NaHC0 3 and 5.0 mM glucose, is prewarmed to 37° C and gassed with a mixture of 95% oxygen/5% carbon dioxide.
  • a balloon catheter connected to a pressure transducer is placed in the left ventricle 5 via the left atrium and is preloaded to a pressure of 40 mm Hg.
  • Coronary perfusate flow is measured continuously, and changes in heart rate and left ventricular contractility are also monitored continuously.
  • Q Each experiment consists of a 30 minute equilibrium period during which coronary flow is stabilized at 9-12 ml/min. Following this period, a vasoconstrictor is injected 3 times at 40 minute intervals into the cannulated aorta.
  • the mean decrease in coronary flow obtained with three consecutive injections of U-46619 in the absence of the test substance is taken to be 100% and 5 the percent inhibition of this effect in the presence of increasing concentrations of the test drugs is calculated.
  • Complete individual dose-response curves for each test drug are generated in five hearts, enabling the calculation of the dose for the half- maximal antivasoconstrictor effect (ID 50 ) .
  • Mean arterial pressures are derived electronically from the blood pressure wave.
  • Mean pretreatment values of mean arterial pressure are in the range of 160-220 mm Hg.
  • Reference Agents (ED 100 , ⁇ g/ml) ED 100 , ⁇ g/ml:
  • Insulin is a hormone that activates various biochemical processes in the body, the most well known being facilitation of glucose transport over cell membranes and activation of cell growth.
  • the development of insulin resistance is common both in diabetics and nondiabetics, but it is only the glucose transport system that develops resistance to insulin.
  • the normal body produces more insulin and the diabetic patient has to inject higher doses of insulin.
  • insulin also is a growth hormone, the increased insulin concentration induces an accelerated growth of atherosclerotic lesions and increased risk for cardiovascular morbidity and mortality.
  • SHRs spontaneously hypertensive rats
  • Racemic amlodipine, (-) amlodipine, and (+) amlodipine are studied for their effects on glucose transport, insulin plasma concentration and arterial blood pressure.
  • systolic blood pressure measured via tail cuff occlusion
  • fasting levels of plasma insulin and triglycerides are made: (1) systolic blood pressure (measured via tail cuff occlusion) ; (2) fasting levels of plasma insulin and triglycerides; and (3) glucose tolerance.
  • the SHRs receive vehicle or test compound via oral gavage once or twice daily for two or four weeks. Measurements of blood pressure, circulating insulin and triglycerides, and glucose clearance are made following two (and four) weeks of drug administration. Any changes in insulin resistance resulting from the drug treatment are evident as changes in the ratio of plasma glucose/plasma insulin levels and from the glucose tolerance tests.
  • the active ingredient, (-) amlodipine, lactose, and corn starch are blended until uniform; then the magnesium stearate is blended into the resulting powder.
  • the resulting mixture is encapsulated into suitably sized two-piece hard gelatin capsules.
  • Active ingredient (-)amlodipine 0 lactose BP starch BP
  • the active ingredient, (-) amlodipine is sieved through a suitable sieve and blended with lactose, starch, and pregelatinized maize starch.
  • Suitable volumes of purified water are added and the 0 powders are granulated. After drying, the granules are screened and blended with the magnesium stearate.
  • the granules are then compressed into tablets using 7 mm diamter of punches.
  • Tablets of other strengths may be prepared _ by altering the ratio of active ingredient to lactose or the compression weight and using punches to suit.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédés et compositions utilisant l'isomère (-) optiquement pur de l'amlodipine. Ce composé est un médicament puissant destiné à traiter l'hypertension tout en évitant les inconvénients concomitants dus aux effets néfastes qui sont associés au mélange racémique de l'amlodipine. L'isomère (-) de l'amlodipine est également utile pour traiter l'angine de poitrine et d'autres états pathologiques qui peuvent être liés à l'activité de la (-)amlodipine en tant qu'antagoniste des vannes à calcium, tels que l'ischémie cérébrale, les troubles cérébraux, les arhytmies, l'hypertrophie cardiaque, l'angiospasme coronarien, l'infarctus du myocarde, les troubles rénaux et l'insuffisance rénale aiguë, sans les inconvénients concomitants dus aux effets néfastes qui sont associés au mélange racémique d'amlodipine.
EP92925405A 1991-11-26 1992-11-25 Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure Ceased EP0661970A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02019389A EP1262182A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure
EP05107608A EP1614420A3 (fr) 1992-11-25 1992-11-25 Traitment de l'hypertension, de l'angine de poitrine et d'autres troubles avec (-)amlodipine
EP99123828A EP1013275A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79846691A 1991-11-26 1991-11-26
US798466 1991-11-26
PCT/US1992/010145 WO1993010779A1 (fr) 1991-11-26 1992-11-25 Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP99123828A Division EP1013275A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure

Publications (2)

Publication Number Publication Date
EP0661970A4 EP0661970A4 (fr) 1994-12-16
EP0661970A1 true EP0661970A1 (fr) 1995-07-12

Family

ID=25173478

Family Applications (3)

Application Number Title Priority Date Filing Date
EP99123828A Withdrawn EP1013275A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure
EP02019389A Ceased EP1262182A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure
EP92925405A Ceased EP0661970A1 (fr) 1991-11-26 1992-11-25 Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP99123828A Withdrawn EP1013275A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure
EP02019389A Ceased EP1262182A3 (fr) 1991-11-26 1992-11-25 Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure

Country Status (5)

Country Link
EP (3) EP1013275A3 (fr)
JP (1) JPH07501547A (fr)
AU (2) AU3147593A (fr)
CA (1) CA2124445A1 (fr)
WO (1) WO1993010779A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
CA2270022A1 (fr) * 1998-05-14 1999-11-14 Rodney H. Falk Association de dofetilide et d'un inhibiteur calcique
US6333342B1 (en) * 1998-11-04 2001-12-25 Isotechnika, Inc Methods of pharmacological treatment using S(−) amlodipine
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
GB0020842D0 (en) * 2000-08-23 2000-10-11 Pfizer Ltd Therapeutic compositions
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
CN1152013C (zh) * 2001-11-22 2004-06-02 张喜田 一类左旋氨氯地平盐的水合物及其制剂
WO2004024690A1 (fr) 2002-09-11 2004-03-25 Hanlim Pharmaceutical Co., Ltd. Nicotinate de s-(-)-amlodipine, et son procede de preparation
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
US20060035940A1 (en) * 2004-03-16 2006-02-16 Sepracor Inc. (S)-Amlodipine malate
WO2005097191A2 (fr) * 2004-04-04 2005-10-20 Sepracor Inc. Combinaisons comprenant de la (s)-amlodipine et un inhibiteur de la hmg-coa reductase ou un inhibiteur de l'absorption de cholesterol ou les deux a la fois et methodes permettant de reduire l'hypertension
WO2005099699A1 (fr) * 2004-04-07 2005-10-27 Sepracor Inc. Combinaison de (s)-amlodipine et d'un betabloquant, et procedes pour la reduction de l'hypertension
ATE399154T1 (de) * 2004-10-20 2008-07-15 Emcure Pharmaceuticals Ltd Verfahren zur herstellung eines enantiomers von amlodipin in hoher optischer reinheit
WO2008062435A2 (fr) * 2006-08-15 2008-05-29 Alkem Laboratories Ltd. Formes galéniques stabilisées de bésylate d'amlodipine
KR100828883B1 (ko) * 2006-10-27 2008-05-09 씨제이제일제당 (주) 라세믹 암로디핀으로부터 ｓ-(-)-암로디핀의 분리방법
GB0906868D0 (en) * 2009-04-21 2009-06-03 Rabin Bennie Amlodipine salt compositions
EP2322163A1 (fr) * 2009-11-03 2011-05-18 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer
CN110882249B (zh) 2019-11-08 2021-04-30 北京吾为尔创科技有限公司 含苯磺酸左氨氯地平水合物的组合物及其制备方法
CN113209035B (zh) * 2021-05-28 2022-07-08 海南锦瑞制药有限公司 苯磺酸左旋氨氯地平片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089167B1 (fr) * 1982-03-11 1986-10-15 Pfizer Limited Dihydropyridines comme agents anti-ischaémiques et antihypertensifs, procédé pour leur production et compositions pharmaceutiques les contenant
EP0331315A2 (fr) * 1988-02-27 1989-09-06 Pfizer Limited Préparation des R- et S-amlodipines
EP0244944B1 (fr) * 1986-04-04 1990-01-24 Pfizer Limited Sels d'amlodipine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833191U (fr) * 1971-08-23 1973-04-21
GB1438268A (en) * 1974-03-25 1976-06-03 Nelson Research Dev Co Antidepressant
JPS50160949A (fr) * 1974-06-21 1975-12-26
PL233786A1 (fr) * 1980-11-14 1982-05-24 Lilly Co Eli
FR2528046B1 (fr) * 1982-06-08 1985-06-21 Delalande Sa Derives de l'oxazolidinone-2 n-arylee optiquement actifs, inhibiteurs specifiques et reversibles de la monoamine oxydase de type b et leur procede de preparation
NL8202810A (nl) * 1982-07-12 1984-02-01 Duphar Int Res Spasmolytisch werkzaam (+)-secoverine.
IT1203721B (it) * 1983-12-29 1989-02-23 Dompe Farmaceutici Spa Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono
DE3928287A1 (de) * 1989-08-26 1991-02-28 Knoll Ag Verwendung des (+)-enantiomeren von anipamil
AU6758990A (en) * 1989-11-06 1991-05-31 Sepracor, Inc. Analgesic composition containing optically pure s(+) flurbiprofen
EP0519925A1 (fr) * 1989-11-21 1992-12-30 Sepracor, Inc. Emploi de s(-) atenolol optiquement pur dans le traitement de troubles cardiovasculaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089167B1 (fr) * 1982-03-11 1986-10-15 Pfizer Limited Dihydropyridines comme agents anti-ischaémiques et antihypertensifs, procédé pour leur production et compositions pharmaceutiques les contenant
EP0244944B1 (fr) * 1986-04-04 1990-01-24 Pfizer Limited Sels d'amlodipine
EP0331315A2 (fr) * 1988-02-27 1989-09-06 Pfizer Limited Préparation des R- et S-amlodipines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EUR.J.CLIN.PHARMACOL., vol.41, no.2, June 1991 pages 89 - 93 E.J.ARIËNS 'Racemic therapeutics - ethical and regulatory aspects' *
J.CARDIOVASC.PHARMACOL., vol.17, no.4, 1991 pages 587 - 592 W.G.NAYLER ET AL. '(-)[3HÜAmlodipine Binding to Rat Cardiac Membranes' *
J.MED.CHEM., vol.29, no.9, 1986 pages 1696 - 1702 J.E.ARROWSMITH ET AL. 'Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Deivatives Incorporating Basic Substituents' *
J.MED.CHEM., vol.35, no.18, 4 September 1992 pages 3341 - 3344 S GOLDMANN ET AL. 'Determination of the Absolute Configuration of the Active Amlodipine Enantiomer as (-)-S: A Correction' *
SCHWEIZ.MED.WOCHENSCHR., vol.120, no.5, 3 February 1990 pages 131 - 134 E.J.ARIËNS 'Stereoselectivity in pharmacodynamics and pharmacokinetics' *
See also references of WO9310779A1 *

Also Published As

Publication number Publication date
EP1013275A3 (fr) 2001-01-10
AU2221597A (en) 1997-07-31
EP1262182A2 (fr) 2002-12-04
JPH07501547A (ja) 1995-02-16
EP1262182A3 (fr) 2003-02-26
EP1013275A2 (fr) 2000-06-28
CA2124445A1 (fr) 1993-06-10
WO1993010779A1 (fr) 1993-06-10
EP0661970A4 (fr) 1994-12-16
AU3147593A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
US6057344A (en) Methods for treating hypertension, and angina using optically pure (-) amlodipine
WO1993010779A1 (fr) Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure
EP0658110B1 (fr) Utilisation du norastemizole pour le traitement de rhinite allergiques
US5834496A (en) Methods for treating hypertension using optically pure S(-) felodipine
US5508279A (en) Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia
US5571827A (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
WO1993010781A1 (fr) Procede et compositions therapeutiques de l'hypertension, de l'angine et d'autre troubles de la sante au moyen de felodipine s(-) optiquement pure
EP1614420A2 (fr) Traitment de l'hypertension, de l'angine de poitrine et d'autres troubles avec (-)amlodipine
AU2006200150A1 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
AU1354000A (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
AU711231B2 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure S(-) nitrendipine
AU1016900A (en) Methods and compositions for treating hypertension, angina, and other disorders using optically pures(-) felodipine
US5510352A (en) Methods of using (+) doxazosin for the treatment of hypertension
WO1994007476A1 (fr) Procedes et compositions permettant de traiter l'hypertenson, les angines et d'autres affections au moyen de nitredipine s(-) optiquement pure
WO1994009783A1 (fr) Procedes et compositions contenant de la doxazosine (-) utilises dans le traitement de l'adenome prostatique et de l'atherosclerose
JPH0680009B2 (ja) 抗高血圧組み合わせ医薬
JP2636265B2 (ja) 脳循環改善剤
WO1994009782A1 (fr) Procedes et compositions de doxazosine (-) pour le traitement de l'hypertension

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19950920

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20030523

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE